Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.61 |
| ▸ | HTR2C | P28335 | 3/20 | 0.61 |
| ▸ | KDM1A | O60341 | 7/20 | 0.53 |
| ▸ | SRD5A1 | P18405 | 8/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31106553 | 0.88 | HTR2A (0.57) | HTR2AHTR2CKDM1ASRD5A1HTR2B | |
| SCHEMBL24055012 | 0.88 | HTR2A (0.57) | HTR2AHTR2CKDM1ASRD5A1HTR2B | |
| SCHEMBL13799465 | 0.86 | SRD5A1 (0.49) | HTR2AHTR2CKDM1ASRD5A1SRD5A2 | |
| SCHEMBL3169358 | 0.78 | HTR2A (0.46) | HTR2AHTR2C | |
| SCHEMBL19764439 | 0.77 | KDM1A (0.70) | HTR2AHTR2CKDM1ASRD5A1HTR2B | |
| SCHEMBL22589962 | 0.77 | ESR1 (0.35) | HTR2AHTR2CKDM1A | |
| SCHEMBL30695369 | 0.77 | CYP3A4 (0.41) | HTR2AHTR2CKDM1ASIGMAR1 | |
| SCHEMBL9770689 | 0.77 | CYP3A4 (0.41) | HTR2AHTR2CKDM1ASIGMAR1 | |
| SCHEMBL29302321 | 0.77 | KDM1A (0.55) | HTR2AHTR2CKDM1ASRD5A1HTR2B | |
| SCHEMBL24055009 | 0.76 | HTR2A (0.41) | HTR2AHTR2CKDM1ASRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2546256-B1 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARM INC (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-2540726-B1 | Intermediates for the synthesis of E1 activity activating enzyme inhibitors | MILLENNIUM PHARM INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190255052-A1 | Inhibitors of E1 Activating Enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| CN-110003216-A | E1 activating enzyme inhibitors | 千禧药品公司 | 2019-07-12 | — | — | CN | disclosed |
| CN-106008512-B | E1 activating enzyme inhibitors | 千禧药品公司 | 2019-03-12 | — | — | CN | disclosed |
| EP-2178880-B1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | MILLENNIUM PHARM INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9718788-B2 | Heteroaryl compounds useful as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170050935-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
| CN-106008512-A | INHIBITORS OF E1 ACTIVATING ENZYMES | 千禧药品公司 | 2016-10-12 | — | — | CN | disclosed |
| US-8008307-B2 | Heteroaryl compounds useful as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| EP-2049491-B1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARM INC (US) | 2010-10-20 | — | — | EP | disclosed |
| CN-101516850-A | Heteroaryl compounds useful as inhibitors of E1 activating enzyme | MILLENNIUM PHARM INC (US) | 2009-08-26 | — | — | CN | disclosed |
| EP-2049491-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-22 | — | — | EP | disclosed |
| CN-101379061-A | E1 activating enzyme inhibitor | MILLENNIUM PHARM INC (US) | 2009-03-04 | — | — | CN | disclosed |
| EP-1989206-A2 | INHIBITORS OF E1 ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080051404-A1 | Heteroaryl compounds useful as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| WO-2008019124-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2007092213-A2 | INHIBITORS OF E1 ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | HTR2A 4708/4885HTR2C 4747/4885KDM1A 513/4885 |
| US-20080051404-A1 | Heteroaryl compounds useful as inhibitors of E1 activating enzymes | RCE1, ECE1, UBE2E1 | HTR2A 4536/4885HTR2C 4580/4885KDM1A 961/4885 |
| US-20190255052-A1 | Inhibitors of E1 Activating Enzymes | ECE1, RNASE1, RCE1 | HTR2A 4708/4885HTR2C 4747/4885KDM1A 513/4885 |
| US-20170050935-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | RCE1, ECE1, UBE2E1 | HTR2A 4536/4885HTR2C 4580/4885KDM1A 961/4885 |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | HTR2A 4708/4885HTR2C 4747/4885KDM1A 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.